



PLATINUM-**SENSITIVE** RECURRENCE UCI 15-31\*\* MORPHOTEK: Randomized, double-blind, placebo-controlled, phase II of Farletuzumab (MORAb-003) with Carboplatin-Paclitaxel or Carboplatin-PLD in women with Low CA-125 platinum-S disease.

UCI 15-03 JANSSEN OVA-3006: Randomized, open-label study of PLD +/- Yondelis for platinum-resistant disease initially platinum-sensitive (2 prior regimens)

GOG 3013 Pfizer: A Phase III, Multicenter, randomized, open-label study of Avelumab (MSB0010718C) Alone or in combination with and without Pegylated Liposomal

Doxorubicin in pts. with Platinum-resistant/refractory

ovarian cancer.

UCI 00-00 ACERTA: Phase 2 proof-of-concept study of ACP-196 (Bruton tyrosine kinase inhibitor) with and without Pembrolizumab (anti-PD1) not open yet

UCI 13-41 MILO Study: Randomized, Phase 3 MEK162 vs physician's choice chemoRx for low-grade serous

PLATINUM-

RESISTANT **RECURRENCE**